Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 1Mesothelioma, Malignant 1Fallopian Tube Endometrioid Adenocarcinoma 1

Interventions

pembrolizumab 5Cisplatin 5Platinum 4Pemetrexed 41,2-diaminocyclohexaneplatinum II citrate 4Nivolumab 3Cyclophosphamide 3fludarabine 2atezolizumab 2Ipilimumab 2Carboplatin 2tremelimumab 1sargramostim 1methoxyamine 1lenvatinib 1cediranib 1anetumab ravtansine 1UV1 vaccine 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Interleukin-2 1Imprint II 1Immunotherapy, Adoptive 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Bevacizumab 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Mesothelioma, Malignant × anetumab ravtansine × Clear all
NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
49 enrolled 20 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡